1. Meaning 

Data-driven biosurveillance is the systematic collection, integration, analysis and interpretation of biological, medical, environmental and population-level data to detect, monitor, predict or respond to threats to public health.

It combines traditional disease surveillance with modern data technologies, including artificial intelligence (AI), genomic sequencing, electronic health records, laboratory reporting, wastewater monitoring, wearable devices and mobility data.

The central legal question is:

To what extent may governments, public health authorities and private organisations collect and analyse biological and personal data to protect public health without violating privacy, equality, confidentiality and other fundamental rights?

Data-driven biosurveillance operates at the intersection of public health law, constitutional law, data protection, administrative law, human rights, cybersecurity and scientific research regulation.

Training on Implementing Integrated Disease Surveillance and Response (IDSR) - ForElite Training Institute

Epidemiological data

Records of infections, symptoms, hospital admissions, deaths and disease outbreaks help authorities identify patterns and allocate healthcare resources.

Details - Public Health Image Library(PHIL)

Genomic surveillance

Pathogen sequencing can identify variants, trace transmission patterns and detect emerging antimicrobial resistance.

Our Work - 2021 | What We Do | NCEZID | CDC

Environmental biosurveillance

Wastewater and environmental sampling can reveal the circulation of pathogens without requiring every individual to undergo testing.

2. Principal forms of data-driven biosurveillance

The legal position depends on who collects the data, whether individuals can be identified, the purpose of processing, the applicable jurisdiction and whether surveillance is voluntary or compulsory.

3. Legal framework governing data-driven biosurveillance in India

In India, biosurveillance must be assessed through constitutional protections, applicable data-protection legislation, public-health statutes and rules governing the particular surveillance programme.

A. Constitutional provisions

Article 21 — Right to life, personal liberty and privacy

The right to privacy includes protection against unjustified intrusion into personal and informational privacy. Health records, biometric identifiers and identifiable genomic data can reveal intimate information about a person.

Article 14 — Equality before the law

Surveillance systems must not arbitrarily target particular communities or impose discriminatory burdens on people based on caste, socioeconomic status, disability, geography or other protected or relevant characteristics.

Article 19 — Fundamental freedoms

Surveillance may indirectly chill freedom of movement, association, expression and participation in public life, depending on how the information is collected and used.

Articles 32 and 226 — Constitutional remedies

Affected persons may approach the Supreme Court or High Courts, as applicable, to challenge unlawful state action and seek appropriate remedies.

B. Statutory framework

Important qualification: These laws do not collectively establish an unlimited power to monitor every person. The legal basis must be assessed for the specific activity, the responsible authority, the data involved and the purpose for which the information is processed. Ethical guidance and professional standards must also be distinguished from binding legislation.

4. Leading judicial decisions and their relevance

The following cases provide important principles for evaluating biosurveillance. Some concern biometric identification, DNA retention or telecommunications data rather than disease surveillance itself; their relevance is by analogy to comparable privacy and proportionality issues.

Case 1: Justice K.S. Puttaswamy (Retd.) v. Union of India (2017)

Supreme Court of India · (2017) 10 SCC 1

The nine-judge Constitution Bench recognised privacy as a fundamental right protected by the Indian Constitution. The judgment discussed bodily integrity, informational privacy, dignity and individual autonomy.

Indian Kanoon

Legal principle: State collection and use of personal information must respect constitutionally protected privacy.

Application to biosurveillance:

A public-health authority cannot assume that collecting sensitive data is lawful merely because the data could be useful.

Large-scale linkage of medical, genomic and location datasets requires careful scrutiny.

A legitimate public-health objective does not, by itself, justify every means of achieving it.

The proportionality framework associated with Puttaswamy requires attention to legality, legitimate state purpose, necessity and proportionality, together with safeguards against abuse.

Case 2: K.S. Puttaswamy v. Union of India (Aadhaar judgment, 2018)

Supreme Court of India · (2019) 1 SCC 1

The Court examined the constitutional validity of the Aadhaar framework, including biometric collection, data security, purpose limitations and concerns about surveillance. The majority upheld the Aadhaar scheme in substantial part while invalidating or limiting particular provisions and uses.

Indian Kanoon+1

Legal principle: The legality of a large-scale identity-data system depends on its statutory framework, purpose, safeguards and proportionality; the judgment did not authorise unrestricted data aggregation.

Application to biosurveillance: A national disease database should have defined purposes, access controls, restrictions on onward sharing and safeguards against linking health records to unrelated identity or enforcement systems without lawful authority.

Case 3: District Registrar and Collector, Hyderabad v. Canara Bank (2005)

Supreme Court of India · (2005) 1 SCC 496

The Court considered statutory powers permitting access to private documents and stressed the importance of privacy in the face of intrusive official inspection. The decision is discussed in the later Aadhaar litigation.

Indian Kanoon

Legal principle: Statutory powers of inspection and access to private material are not immune from constitutional scrutiny.

Application to biosurveillance: A public authority's ability to demand laboratory records, access identifiable medical information or inspect private datasets must be grounded in law and exercised within the limits of the relevant power.

Case 4: Digital Rights Ireland Ltd v. Minister for Communications (2014)

Court of Justice of the European Union · Joined Cases C-293/12 and C-594/12, EU:C:2014:238

The Court invalidated the EU Data Retention Directive because its broad retention requirements interfered disproportionately with the rights to privacy and personal-data protection under Articles 7 and 8 of the EU Charter.

Cour de justice de l’Union européenne

Legal principle: Broad retention of personal data can be disproportionate when it lacks sufficiently tailored limits and safeguards.

Application to biosurveillance: Indefinite retention of identifiable health records, genomic sequences or movement histories is difficult to justify without a specific lawful purpose and a defensible retention period.

This is an EU judgment, not binding Indian precedent, but it offers a useful comparative constitutional and data-protection analysis.

Case 5: Tele2 Sverige AB v. Post- och telestyrelsen and Secretary of State for the Home Department v. Watson (2016)

Court of Justice of the European Union · Joined Cases C-203/15 and C-698/15, EU:C:2016:970

The Court restricted general and indiscriminate retention of communications traffic and location data under the EU ePrivacy framework. It emphasised limits on retention and access, especially where highly revealing personal information is involved.

Cour de justice de l’Union européenne+1

Application to biosurveillance: Continuous collection of mobility or contact data to predict outbreaks should be assessed for necessity, targeting, retention and access restrictions. Information collected for epidemic management should not automatically become a general-purpose population-monitoring resource.

Case 6: S. and Marper v. United Kingdom (2008)

European Court of Human Rights · Applications Nos. 30562/04 and 30566/04

The Grand Chamber held that the blanket and indefinite retention of fingerprints, cellular samples and DNA profiles of people who had not been convicted violated Article 8 of the European Convention on Human Rights. The retention policy failed to strike a fair balance between public and private interests.

Application to biosurveillance: Biological samples and genomic identifiers warrant particular care because they can disclose enduring information about individuals and their relatives. A system should distinguish between retaining a pathogen sequence for scientific purposes and retaining identifiable human biological material indefinitely.

This decision is especially relevant when designing DNA databases, biobanks and long-term biological surveillance programmes.

Case 7: Carpenter v. United States (2018)

Supreme Court of the United States · 585 U.S. 296 (2018)

The Court held that the government's acquisition of historical cell-site location records in the circumstances of the case constituted a Fourth Amendment search, generally requiring a warrant supported by probable cause.

Application to biosurveillance: Combining health records with extensive location histories can reveal patterns of personal life far beyond the original public-health purpose. The legal authority to access one dataset should not automatically be treated as authority to construct a comprehensive personal profile from several datasets.

This US constitutional ruling is comparative authority rather than binding law in India.

5. Core legal issues in data-driven biosurveillance

A. Privacy and informed consent

Biosurveillance often involves processing data that individuals did not provide directly to a surveillance authority. For example, wastewater monitoring may use pooled biological material, while genomic surveillance may use samples originally collected for clinical treatment.

The law must distinguish between:

Consent-based processing: An individual knowingly agrees to a defined collection or research purpose.

Statutorily authorised surveillance: Processing is authorised by applicable legislation, even where individual consent is not the legal basis.

Secondary use: Information collected for treatment, research or another purpose is reused for outbreak prediction or a different public function.

Anonymous or aggregated monitoring: Data is processed without directly identifying individuals, although re-identification may remain possible.

Consent is not the only possible lawful basis for public-health processing, but the absence of a consent requirement does not remove other legal obligations.

Example: A hospital may be required by law to report a specified infectious disease. That does not necessarily authorise unrestricted disclosure of the patient's entire medical history to unrelated government agencies.

B. Data minimisation and purpose limitation

A surveillance authority should collect only the information reasonably necessary for its defined purpose.

Suppose a city wants to identify an emerging respiratory outbreak. It may be sufficient to analyse aggregate hospital admissions, diagnostic results and wastewater trends. Collecting every resident's continuous GPS location, full genome and unrelated clinical records may be excessive unless separately justified by law and evidence.

The principal legal questions are:

Is the information necessary for the stated public-health objective?

Could substantially the same objective be achieved using less intrusive data?

Are the categories of information and persons monitored appropriately limited?

Is the data retained only for a defensible period?

Is subsequent use restricted and documented?

These considerations reflect privacy and proportionality principles, including those developed in Puttaswamy and comparative data-retention cases.

C. Genomic privacy and familial implications

Human genomic information presents special risks because it may reveal inherited conditions, biological relationships, ancestry-related information and predispositions to disease.

A person's genome can also convey information about biological relatives who never provided samples or consented to the original research.

Potential legal disputes include:

Unauthorised disclosure of genomic results.

Re-identification of supposedly anonymised genetic datasets.

Use of genomic information for employment or insurance decisions.

Sharing human genetic data with overseas laboratories.

Reuse of biobank samples beyond the scope of the original consent or lawful authority.

Legal implication: Removing a patient's name does not necessarily render genomic data anonymous. Robust governance should consider indirect identifiers, genetic linkage and the risk of re-identification.

D. Algorithmic bias and discrimination

AI systems can detect patterns across large datasets, but they may also reproduce deficiencies in the underlying data.

For example, if a disease-prediction model is trained primarily on records from urban hospitals, it may underestimate disease burdens in rural populations with limited access to healthcare.

This creates potential concerns involving:

Unequal allocation of testing and medical resources.

Disproportionate monitoring of particular communities.

False-positive outbreak alerts.

Stigmatisation of neighbourhoods or population groups.

Unexplained or unreviewable administrative decisions.

A model's prediction should not automatically be treated as proof that a person is infected, dangerous or responsible for transmitting disease. Decisions affecting individuals require appropriate validation, procedural safeguards and human review.

E. Data sharing between public health and law enforcement

One of the most significant risks arises when information collected for disease control is repurposed for policing, immigration enforcement, employment screening or unrelated investigations.

The legal analysis should consider the original collection purpose, the proposed secondary use, statutory authority, necessity, confidentiality rules and the consequences for affected people.

Public-health emergencies may justify particular disclosures, but they do not create a universal exemption from privacy law.

F. Cybersecurity and data breaches

Biosurveillance databases may contain highly sensitive clinical, genomic and epidemiological information. Unauthorised access could cause identity theft, discrimination, extortion, reputational damage or exposure of family relationships.

Relevant safeguards include encryption, role-based access, audit logs, secure transfer protocols, separation of identifying information from research datasets, vulnerability testing and incident-response procedures.

Liability may arise under applicable data-protection legislation, confidentiality duties, contracts, negligence principles or specific cybersecurity provisions, depending on the facts and governing law.

6. Legal liability of stakeholders

Liability is not automatic merely because a prediction is inaccurate or a system produces an adverse outcome. Courts and regulators may examine the applicable duty, the defendant's conduct, causation, available defences and the loss suffered.

7. A practical legal-compliance framework

A defensible data-driven biosurveillance programme should incorporate the following controls.

1. Establish legal authority

Identify the legislation, regulation, public-health order or other valid legal basis authorising collection and use. Define the responsible authority and its limits.

2. Define the public-health purpose

Specify the disease, population, intervention and decisions the system is designed to support. Prohibit incompatible secondary uses unless separately authorised.

3. Conduct a privacy and risk assessment

Assess re-identification, group privacy, discriminatory impacts, data-linkage risks, cybersecurity and the availability of less intrusive alternatives.

4. Limit access and retention

Use access controls, encryption, audit trails, retention schedules and secure deletion. Separate identifiable clinical information from aggregate surveillance outputs where feasible.

5. Validate analytical systems

Test predictive models for accuracy, bias, uncertainty and performance across populations. Maintain human oversight over consequential decisions.

6. Ensure accountability

Document data flows, maintain records of access and disclosure, establish breach-response procedures and provide appropriate avenues for complaints and legal remedies.

8. Application during public-health emergencies

During an epidemic or pandemic, data-driven biosurveillance may support early detection, contact tracing, resource planning and identification of emerging variants.

However, emergency powers should be assessed against the same fundamental questions of legality, necessity, proportionality and accountability.

For example, an outbreak-monitoring programme that initially collects identifiable contact-tracing information should specify:

When individual identification is necessary.

Which officials may access identifiable records.

Whether information may be disclosed to other agencies.

When identifiable records must be deleted or de-identified.

How people can challenge erroneous records or unlawful restrictions.

Emergency measures should not become permanent surveillance systems by default. Their continuation beyond the emergency requires an independently defensible legal basis.

9. Remedies for unlawful biosurveillance

Depending on the jurisdiction and facts, affected individuals or organisations may seek:

Constitutional judicial review: Challenge unlawful state surveillance or disproportionate interference with fundamental rights.

Data-protection remedies: Use applicable complaint, correction, erasure or other statutory procedures where available.

Injunctive relief: Seek an order restricting unlawful disclosure, collection or use of information.

Compensation or damages: Pursue relief where the applicable statute or civil law permits it.

Regulatory investigation: Report breaches to a competent data-protection, health or cybersecurity authority.

Institutional review: Challenge research practices through appropriate ethics committees, institutional procedures or other competent bodies.

The availability of each remedy depends on the applicable legislation, the nature of the defendant and the evidence establishing the alleged violation.

10. Critical legal assessment

Data-driven biosurveillance creates a genuine tension between collective health protection and individual liberty. Effective surveillance can save lives, but excessive collection and opaque data sharing can undermine public trust, discourage healthcare participation and expose vulnerable communities to harm.

The principal lessons from the cases discussed are:

Puttaswamy establishes the constitutional importance of privacy and the need to justify state interference.

The Aadhaar judgment illustrates the importance of statutory limits and safeguards in large-scale biometric systems.

Canara Bank highlights the need to scrutinise intrusive statutory inspection powers.

Digital Rights Ireland and Tele2/Watson demonstrate the dangers of indiscriminate data retention.

S. and Marper illustrates why indefinite retention of sensitive biological identifiers can be disproportionate.

Carpenter demonstrates how aggregated location information can reveal highly personal details.

These decisions do not establish a single universal rule for every biosurveillance system. Their legal weight varies by jurisdiction, and the actual lawfulness of a programme depends on its design, legal authority and operation.

Conclusion

Data-driven biosurveillance is legally defensible when it is authorised by law, directed at a legitimate public-health objective, proportionate to the risks addressed and supported by meaningful privacy, security and accountability safeguards.

In India, Article 21 and the Puttaswamy jurisprudence provide a central constitutional framework for examining intrusive surveillance. Applicable data-protection legislation, public-health laws, confidentiality obligations and research requirements must then be considered in context. In particular, the Digital Personal Data Protection Act, 2023 must be applied with regard to its operative provisions, commencement notifications and applicable exemptions.

The strongest legal approach is not to prohibit all data-driven surveillance, but to ensure that public-health benefits are achieved without unnecessary collection, indefinite retention, discriminatory profiling or unauthorised secondary use.

For a more targeted legal analysis, the next useful step would be to examine Data-Driven Biosurveillance under Indian law, including constitutional challenges, statutory powers, genomic-data governance and relevant judicial precedents.